[SARS-CoV-2 infection: Available data on 15th April 2021].
Infection à SARS-CoV-2 : connaissances au 15 avril 2021.
COVID-19
COVID-19.
Corticosteroids
Corticoïdes
Facteurs de risque
Risk factors
SARS-CoV-2
Traitement
Treatment
Journal
Revue des maladies respiratoires
ISSN: 1776-2588
Titre abrégé: Rev Mal Respir
Pays: France
ID NLM: 8408032
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
18
02
2021
accepted:
25
04
2021
pubmed:
25
5
2021
medline:
25
6
2021
entrez:
24
5
2021
Statut:
ppublish
Résumé
Since January 2020, when the first cases of SARS-CoV-2 infection were diagnosed in France, pulmonologists have been at the heart of the crisis and should be responsible for the management of acute COVID-19 (and any possible sequelae) BACKGROUND: Many drugs have been evaluated or are currently under evaluation as possible specific treatment for SARS-CoV-2. Nevertheless, as of April 15, 2021, the only recommended treatment in current practice is the "standard of care", i.e. the symptomatic management of infection with SARS-CoV-2. This review presents the state of knowledge on COVID-19 in the acute phase (virological, immunological, epidemiological and therapeutic data) available on 15th April, 2021. A large number of clinical trials are currently ongoing. It is important to propose to patients the opportunity to participate in clinical trials and to structure the research in order to complete the studies. Current management is based on oxygen therapy, thromboprophylaxis and in some cases corticosteroids. No antiviral therapy is currently recommended. These data are constantly evolving.
Identifiants
pubmed: 34024645
pii: S0761-8425(21)00235-7
doi: 10.1016/j.rmr.2021.04.014
pmc: PMC8086807
pii:
doi:
Types de publication
Journal Article
Review
Langues
fre
Sous-ensembles de citation
IM
Pagination
616-625Informations de copyright
Copyright © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.